June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
THE EFFICACY OF SINGLE INTRAVITREAL RANIBIZUMAB INJECTION IN ACUTE NONARTERITIC ISCHEMIC OPTIC NEUROPATHY
Author Affiliations & Notes
  • ALI OSMAN SAATCI
    Ophthalmology Department, Dokuz Eylul University, Izmir, Turkey
  • Okan Taskin
    Ophthalmology Department, Dokuz Eylul University, Izmir, Turkey
  • Ozlem Barut Selver
    Ophthalmology Department, Dokuz Eylul University, Izmir, Turkey
  • Aylin Yaman
    Ophthalmology Department, Dokuz Eylul University, Izmir, Turkey
  • Meltem Soylev Bajin
    Ophthalmology Department, Dokuz Eylul University, Izmir, Turkey
  • Footnotes
    Commercial Relationships ALI OSMAN SAATCI, None; Okan Taskin, None; Ozlem Barut Selver, None; Aylin Yaman, None; Meltem Soylev Bajin, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4934. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      ALI OSMAN SAATCI, Okan Taskin, Ozlem Barut Selver, Aylin Yaman, Meltem Soylev Bajin; THE EFFICACY OF SINGLE INTRAVITREAL RANIBIZUMAB INJECTION IN ACUTE NONARTERITIC ISCHEMIC OPTIC NEUROPATHY. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4934. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate the effect of a single intravitreal ranibizumab injection in eyes with acute nonarteritic ischemic optic neuropathy (NAION).

Methods: In this retrospective clinical data analysis, 17 eyes of sixteen patients who experienced a visual loss with a duration of 15 days or less comprised the study group. In addition to standard opthalmic examination, retinal nerve fiber layer thickness (RNFLT) analysis with spectral domain OCT was also performed prior to injection, one, three, six months and one year after the injection.Two subgroups were also statistically analyzed according to the visual loss duration. (Group one, visual loss duration less than eight days and group two, visual loss duration between eight and 15 days.)

Results: The mean time between visual loss and intravitreal injection was 7.5 days (Range, 2-15 days). Mean age of patients was 59 years (Range, 41-90 years). Male to female ratio was 6:10. After a single dose of ranibizumab injection, visual gain was noted in 14 of 17 study eyes. In two eyes, visual acuity was minimally reduced and no change was noted in the remaining eye with an initial visual acuity of hand motions. While preinjection mean best-corrected visual acuity (BCVA) was 1.45 ±0.88 logMar unit, postinjection mean BCVA was 1.00±0.68, 0.86 ±0.70, 0.80 ±0.71, 0.77 ±0.70 logMar unit respectively at the first week, first month, third month and first year. In all patients, the mean RNFLT dramatically decreased after the injection during the follow- up. While preinjection mean RNFLT was 210 ±38 µm, postinjection mean RNFLT was 162.11±40.2, 94±27, 71.23±22.5 and 57 ±18 µm respectively at the first week, first month, third month and first year. The improvement in visual acuity and RNFLT was better in the group of eyes with disease duration less than eight days but statitistical analysis was not significant when two groups were compared. No injection related complication was noted during the follow-up period.

Conclusions: Intravitreal ranibizumab may be a promising treatment option in eyes with acute NAION .

Keywords: 561 injection • 629 optic nerve • 552 imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound)  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×